INTRODUCTION
Animal models have been used as the front line in predicting efficacy and finding toxicities for cancer chemotherapeutic agents before entering the clinic. This has resulted in the development of many different animal models of malignant disease. The bulk of these models can be separated into two groups: first, grafts of tumor material (syngeneic or xenogeneic) into immunocompetent or immunodeficient animals, respectively; and second, genetically engineered mice that recapitulate a specific cancer genotype. Although these two groups both possess unique qualities, the usefulness of genetically engineered mice for identifying novel compounds that subsequently demonstrate significant clinical activity against the appropriate histology remains to be validated.
The discovery of nude athymic (nu/nu) mice that were T-cell deficient 1 , and later B-cell-deficient and T-cell-deficient severe combined immunodeficient (scid/scid) mice 2 , allowed the routine and efficient transplantation and propagation of human tumor tissues (xenografts) in mice. These mouse strains allow established in vitro human cell lines to be propagated subcutaneously, reconstituting solid tumors. Human tumor tissue explants obtained from biopsy or autopsy can also be transplanted directly into these strains of mice.
The predictive value of these models has been debated extensively. In the National Cancer Institute (NCI) screening program, the activity of an agent in vitro did not predict for activity in either hollow-fiber assays in vivo or subcutaneous xenograft models, which in turn did not predict for activity against clinical cancer 3 . However, activity of an agent against breast cancer xenografts correlated with clinical activity for the agent against one or more cancers. Furthermore, activity in 30% of tumor models predicted for activity in some clinical cancer. In contrast to the NCI experience, retrospective analysis showed that xenograft models, but not allografts of murine tumors, can be useful for predicting the phase 2 clinical trial performance (at least for ovarian and non-small-cell lung cancers) when panels of tumors are used 4 . Other studies have found the predictive value of xenograft models to be variable 5, 6 . For childhood cancers, xenograft models have been relatively accurate in identifying clinically active agents 7 and effective drug combinations, particularly when differences in drug exposure between tested animals and humans are taken into account 8 .
However, the reason why the models failed to accurately predict activity in the appropriate clinical histology in the NCI program is of concern. In part, this might be a consequence of using continuous cell lines in vitro as the source of material for starting xenografts. In vitro culture for several years might select for clones that are no longer representative of the original tumor. For example, mutation of p53 or silencing of the gene encoding the DNA repair protein MGMT occurs relatively frequently in culture 9, 10 . Alternatively, as the culture of only a minority of tumor biopsies results in the generation of continuous cell lines, the process of in vitro culture might itself select for subsets of lines that are not representative of the disease per se.
Goldin and colleagues originally proposed using panels of xenografts to represent the 'clinical' disease 11 . However, with the continuing molecular-genetic subclassification of tumors within a histology it is clear that many tumor lines will be required to simulate the compound genetic diversity needed to model a clinical population with respect to, for example, estrogen receptor status or BRCA1 mutations in breast carcinoma. Similarly, modeling the dysregulation of the multiple membrane receptor kinase-signaling pathways -that is, endothelial growth factor (EGF), plateletderived growth factor receptor (PDGFR), insulin-like growth factor I (IGF-I), basic fibroblast growth factor (bFGF) and hepatocyte growth factor/scatter factor (HGF-SF) -reported for glioblastoma multiforme, or modeling subtypes of childhood sarcomas characterized by different chimeric transcription factors, will require the development of new xenografts.
For xenograft models to be valuable in the development of molecularly-targeted agents, careful molecular characterization is essential to their establishment and validation. Current genomewide molecular-profiling studies indicate the retention of molecular characteristics that define tumor type. The recent study by Whiteford and colleagues 12 demonstrates that, by unsupervised clustering analysis of cDNA-expression profiles, xenografts derived from a histology can cluster accurately with their human counterparts. Similarly, direct comparison of patient tumor biopsy tissue with early-passage xenografts demonstrates high concordance in gene expression and even greater similarity in genomic alterations when tumors are propagated in mice. Historically, attempts have been made to use heterografts under the subrenal capsule as a method of predicting patient tumor chemosensitivity 13 . However, the low success of heterografting, and the relatively long time needed to establish tumor heterografts make this use of xenografts suboptimal. Rather, the value of panels of xenografts representing a particular histotype is to select novel agents that have a high response rate against that tumor type in patients, when administered to mice at doses that result in clinically achievable system exposures.
In addition to athymic nude mice, human tumor xenografts can be propagated in the subcutaneous space of scid/scid mice, non-obese (NOD)-scid mice and recombination-activating gene 2 (Rag2)-knockout mice. The protocol described covers the basic technique for establishing new tumors from patient biopsy, or for the serial transfer of mouse-propagated tumors. Although certain strains (NOD-scid) appear more receptive for growing leukemias 14 , our overall 'success' rate for establishing and serially propagating childhood solid tumors and brain tumors is high. For rhabdomyosarcoma and osteosarcoma, the success rates are 17/42 (40%) and 16/34 (47%), respectively. For pediatric brain tumors, rhabdoid tumors of the CNS and kidney, and Wilms tumor (nephroblastoma), successful grafts were obtained from 49 of 156 samples (31%), which included some that were found subsequently to be nonmalignant. Interestingly, the success rate with glioblastoma is low (o20%), which might reflect the requirement for orthotopic heterotransplantation for these brain tumors. Thus, overall, the successful heterotransplantation rate is higher than that reported for adult carcinomas, particularly those of the prostate and breast. This might reflect a difference in the biology of pediatric cancers, or the difficulty in heterografting hormone-dependent tumors. It is, however, important to realize that the chemosensitivity of human tumors heterografted into different strains might differ, suggesting that the genetic background of the host mouse might be a factor in determining tumor responsiveness 15 .
In this protocol, we present methods for establishing a tumor xenograft in mice from tumor tissue or cells from cell culture.
MATERIALS

REAGENTS
. CB17SC-M-F scid -/-mice, 6-10 weeks old (Taconic Farms, mod. no. (i) Harvest cells grown in monolayer culture during the exponential growth phase using trypsin or appropriate enzymes for the specific cell line. Suspend cells in medium plus serum.
CB17SC-M) ! CAUTION
! CAUTION Cells should be tested to ensure that they are not contaminated with viruses that would be harmful to immunodeficient mice. This can be accomplished using the traditional murine antibody production (MAP) test or one of the more sensitive PCR-based tests, such as the University of Missouri Research Animal Diagnostic Laboratory (RADIL) infectious microbe PCR amplification test (IMPACT). ! CAUTION Appropriate protective measures should be taken to ensure that workers are not exposed to waste anesthetic gases using suitable activated-charcoal capture or exhaust venting.
4| After a mouse reaches sufficient anesthetic depth, remove it from the chamber and place it (ventral side down) in a properly sized nose cone, configured according to the manufacturer's recommended settings, with the dorsal side facing upwards.
To confirm anesthetic depth, pinch the rear foot lightly. If no kicking response is present, continue with the procedure. (i) Agitate the cell suspension to prevent the cells from settling, and withdraw from the sterile tube into a 1-cc TB syringe with the needle removed. (ii) Lift the skin of the mouse to separate it from the underlying muscle and inject, with a 21 G needle, 0.1 ml of the cell suspension (1 Â 10 7 cells) subcutaneously.
6|
Place the animal in a clean cage and observe for 10-15 min to ensure recovery from the anesthetic.
ANTICIPATED RESULTS
For the first week following implantation, a small bump will be visible where the tumor was inserted and this will then disappear. At 1-4 months (and occasionally up to 1.5 yr) following implantation, a tumor will begin to appear at the site of implantation. This visualization is made easier by trimming the hair from the haunch using animal trimmers. When the tumor reaches B1.5 cm in diameter, it can be excised, dissected into 5 mm cubes and transplanted into additional mice using the same procedure. It is important to characterize the tumor at this point, to ensure that it is derived from the starting material. The most accurate method for doing this is to harvest genomic DNA from both the primary sample and the established xenograft tumor. These separate DNA samples can be analyzed by single-nucleotide polymorphism (SNP) array to determine whether they arise from the same sample. Once tumor integrity has been confirmed, the xenograft can be transplanted into additional mice for chemosensitivity testing. Following transplantation, tumors should be allowed to grow to 200-500 mm 3 before initiation of treatment. 
